A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
Latest Information Update: 24 Jan 2025
At a glance
- Drugs CNTX 0290 (Primary) ; Fepixnebart (Primary) ; LY 3526318 (Primary) ; LY 3857210 (Primary)
- Indications Back pain; Diabetic neuropathies; Neuropathic pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Eli Lilly and Company
- 09 Dec 2024 Planned End Date changed from 25 Apr 2027 to 1 Apr 2027.
- 09 Dec 2024 Planned primary completion date changed from 25 Apr 2027 to 1 Apr 2027.
- 09 Aug 2024 Results provide baseline demographics of participants screened in CPMP and randomized to an Intervention Specific Appendix (ISA), presented at the 20th World Congress on Pain